Research Progress of Nanodelivery Systems for Pancreatic Cancer

Zongfan Zhang

doi:10.54097/ze3v4092

Authors

Zongfan Zhang

DOI:

https://doi.org/10.54097/ze3v4092

Keywords:

Pancreatic cancer; Nanodelivery Systems; Research progress.

Abstract

Pancreatic cancer is characterised by its aggressive nature and poor prognosis, mainly due to its complex biology. The tumour microenvironment plays an important role and is composed of different cellular components that enable tumour growth and metastasis. Cellular heterogeneity further complicates treatment, as different cell populations within the tumour behave and respond differently to treatment. Against this background, nano-delivery systems such as liposomes, micelles and exosomes have emerged as promising strategies to improve drug delivery and efficacy. These systems can improve bioavailability and targeting and overcome some of the limitations of conventional therapies. However, challenges remain in optimising drug delivery mechanisms, ensuring biocompatibility and managing the complexity of the tumour microenvironment. Future research should focus on overcoming these obstacles in order to realise the full potential of nanotransduction systems in the treatment of pancreatic cancer.

Downloads

Download data is not yet available.

References

[1] Zavoral, M., Minarikova, P., Zavada, F., Salek, C., & Minarik, M. "Molecular biology of pancreatic cancer." World Journal of Gastroenterology, 2011, 17(24): 2897.

[2] Versemann, L., Hessmann, E., & Ulisse, M. "Epigenetic therapeutic strategies to target molecular and cellular heterogeneity in pancreatic cancer." Visceral Medicine, 2022, 38(1): 11-19.

[3] Klein, A.P., et al.. "Pancreatic cancer: epidemiology and risk factors." Nature Reviews Gastroenterology & Hepatology, 2019, 16(7).

[4] Nan, N., Kim, O.R., & Lee, M.A. "β-Catenin expression is associated with cell invasiveness in pancreatic cancer." The Korean Journal of Internal Medicine, 2019, 34(3): 618.

[5] Ming,J.,Dan,Z.,Chunxiang,Z.,Chunhong L. "Nanoparticle-based delivery systems modulate the tumor microenvironment in pancreatic cancer for enhanced therapy." Journal of Nanobiotechnology 2021, 19(3): 384.

[6] Di Matteo, P., & Castaing, M. "Challenges and strategies in pancreatic cancer drug delivery." Molecular Cancer Therapeutics, 2020, 19(6): 1129-1139.

[7] O'Reilly, E.M., & Schrag, D. "Emerging biomarkers and imaging techniques for pancreatic cancer diagnosis and monitoring." Cancer Research, 2023, 83(8): 1234-1245.

[8] Zhao, J. F., Zou, F. L., Zhu, J. F., et al. "Nano-drug delivery system for pancreatic cancer: A visualization and bibliometric analysis." Frontiers in Pharmacology, 2022, 13: 1025618.

[9] Bazak, R., Houri, M., El Achy, S., Kamel, S., & Refaat, T. "Cancer active targeting by nanoparticles: a comprehensive review of literature." Journal of Nanomedicine, 2015, 141: 769–784.

[10] Park, J.W. "Liposome-based drug delivery in breast cancer treatment." Breast Cancer Research, 2002, 4: 1-5.

[11] Gabizon, A., & Barenholz, Y. "Pharmacokinetics of pegylated liposomal Doxorubicin: from bench to bedside." Clinical Pharmacokinetics, 2003, 42(5): 419-436.

[12] Malekigorji, M., Curtis, A.D.M., & Hoskins, C. "The Use of Iron Oxide Nanoparticles for Pancreatic Cancer Therapy." Journal of Nanomedicine & Nanotechnology, 2014, 10:15406.Gabizon, A., & Barenholz, Y. "Pharmacokinetics of pegylated liposomal Doxorubicin: from bench to bedside." Clinical Pharmacokinetics, 2003, 42(5): 419-436.

[13] Kunzmann, A., Andersson, B., Thurnherr, T., Krug, H., Scheynius, A., & Fadeel, B."Toxicology of engineered nanomaterials: Focus on biocompatibility, biodistribution and biodegradation." Biochimica et Biophysica Acta, 2010, 1800(6): 700-712.

[14] Dreaden, K. A., Mackey, M. A., & El-Sayed, M. A. (2012). "Size matters: gold nanoparticles in targeted cancer drug delivery." Theranostics, 2(3), 249-263.

[15] Kalluri, R., & LeBleu, V. S. (2020). "The biology, function, and biomedical applications of exosomes." Science, 367(6478).